Literature DB >> 31187523

Primary central nervous system lymphoma: A curable disease.

Tracy T Batchelor1.   

Abstract

Primary central nervous system lymphoma is a rare subtype of non-Hodgkin lymphoma that is confined to the brain, leptomeninges, or the eye and is associated with a relatively poor prognosis compared to other extranodal diffuse large B-cell lymphomas. However, methotrexate-based induction chemotherapy followed by consolidative chemotherapy or high-dose therapy and autologous stem cell transplantation is associated with improved survival and reduced neurotoxicity. Aberrant activation of B-cell receptor signaling and activation of nuclear factor kappa beta is a frequent genetic alteration and offers opportunities for targeted therapies in this lymphoma subtype.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 31187523     DOI: 10.1002/hon.2598

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  13 in total

1.  Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment.

Authors:  G I Cassinelli Petersen; J Shatalov; T Verma; W R Brim; H Subramanian; A Brackett; R C Bahar; S Merkaj; T Zeevi; L H Staib; J Cui; A Omuro; R A Bronen; A Malhotra; M S Aboian
Journal:  AJNR Am J Neuroradiol       Date:  2022-03-31       Impact factor: 3.825

2.  MicroRNAs as Diagnostic Biomarkers in Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.

Authors:  Xiaohong Zheng; Parker Li; Qianqian Dong; Yihong Duan; Shoubo Yang; Zehao Cai; Feng Chen; Wenbin Li
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

3.  Primary Dural Mucosa-associated Lymphoid Tissue Lymphoma Mimicking Falx Meningioma: A Case Report.

Authors:  Issei Takeuchi; Takafumi Tanei; Kyoko Kuwabara; Takenori Kato; Takehiro Naito; Yuta Koketsu; Kento Hirayama; Toshinori Hasegawa
Journal:  NMC Case Rep J       Date:  2022-05-31

4.  Complete response to therapy: why do primary central nervous system lymphoma patients not return to work?

Authors:  Greta Wiemann; Milena Pertz; Uwe Schlegel; Patrizia Thoma; Thomas Kowalski; Sabine Seidel
Journal:  J Neurooncol       Date:  2020-07-31       Impact factor: 4.130

5.  Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).

Authors:  Yanxia Liu; Qingmin Yao; Feng Zhang
Journal:  Int J Oncol       Date:  2021-02-01       Impact factor: 5.650

6.  Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.

Authors:  Qiansong Cheng; Jing Wang; Chenglan Lv; Jingyan Xu
Journal:  Onco Targets Ther       Date:  2021-05-24       Impact factor: 4.147

7.  Preparation and Characterization of Fe3O4@MTX Magnetic Nanoparticles for Thermochemotherapy of Primary Central Nervous System Lymphoma in vitro and in vivo.

Authors:  Xinyu Dai; Jingqing Yao; Yuejiao Zhong; Yuntao Li; Qianling Lu; Yan Zhang; Xue Tian; Zhirui Guo; Tingting Bai
Journal:  Int J Nanomedicine       Date:  2019-12-05

8.  Bilateral middle cerebellar peduncle lesions: Neuroimaging features and differential diagnoses.

Authors:  Jiwei Jiang; Jirui Wang; Meiqing Lin; Xiaoting Wang; Jinli Zhao; Xiuli Shang
Journal:  Brain Behav       Date:  2020-08-05       Impact factor: 2.708

9.  Primary Pituitary Lymphoma in Immunocompetent Patients: A Report on Two Case Studies and the Review of Literature.

Authors:  Lian Duan; Jie Liu; Yan Zhang; Lijia Cui; Xiao Zhai; Boju Pan; Lin Lu; Hui Pan; Yong Yao; Huijuan Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-04       Impact factor: 5.555

10.  Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.

Authors:  Manjunath P Pai; Kenneth C Debacker; Brian Derstine; June Sullivan; Grace L Su; Stewart C Wang
Journal:  Pharmacotherapy       Date:  2020-03-27       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.